Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arcturus Therapeutics Holdings Inc. (ARCT : NSDQ)

• Company Description    Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. Number of Employees: 176

• Price / Volume Information    Yesterday's Closing Price: $21.73 Daily Weekly Monthly 20 Day Moving Average: 929,917 shares Shares Outstanding: 27.16 (millions) Market Capitalization: $590.07 (millions) Beta: 2.39 52 Week High: $23.60 52 Week Low: $8.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.75% 10.80% 12 Week 45.35% 39.53% Year To Date 28.05% 13.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 10628 SCIENCE CENTER DRIVE SUITE 250 - SAN DIEGO,CA 92121 USA ph: 858-900-2660 fax: - ir@arcturusrx.com http://www.arcturusrx.com

• General Corporate Information    Officers Joseph E. Payne - President; Chief Executive Officer and Director Moncef Slaoui - Chairman of the Board Andrew Sassine - Director and Chief Financial Officer Magda Marquet - Director James Barlow - Director Peer Information Arcturus Therapeutics Holdings Inc. (CORR.) Arcturus Therapeutics Holdings Inc. (RSPI) Arcturus Therapeutics Holdings Inc. (CGXP) Arcturus Therapeutics Holdings Inc. (BGEN) Arcturus Therapeutics Holdings Inc. (GTBP) Arcturus Therapeutics Holdings Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03969T109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 27.16 Most Recent Split Date: 11.00 (0.14:1) Beta: 2.39 Market Capitalization: $590.07 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.42 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.30 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.55 Price/Cash Flow: - Price / Sales: 4.83 EPS Growth vs. Year Ago Period: 46.88% vs. Previous Quarter: 34.62% Sales Growth vs. Year Ago Period: -43.24% vs. Previous Quarter: -3.68% ROE 09/30/25 - - 06/30/25 - -24.87 03/31/25 - -27.41 ROA 09/30/25 - - 06/30/25 - -17.75 03/31/25 - -19.01 Current Ratio 09/30/25 - - 06/30/25 - 5.90 03/31/25 - 5.64 Quick Ratio 09/30/25 - - 06/30/25 - 5.90 03/31/25 - 5.64 Operating Margin 09/30/25 - - 06/30/25 - -49.26 03/31/25 - -47.47 Net Margin 09/30/25 - - 06/30/25 - -49.26 03/31/25 - -47.47 Pre-Tax Margin 09/30/25 - - 06/30/25 - -49.44 03/31/25 - -47.72 Book Value 09/30/25 - - 06/30/25 - 8.52 03/31/25 - 8.62 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.06 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 6.03

Powered by Zacks Investment Research ©